Aethlon Medical, Inc. (AEMD) News

Aethlon Medical, Inc. (AEMD): $1.12

-0.21 (-15.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AEMD News Items

AEMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AEMD News From Around the Web

Below are the latest news stories about Aethlon Medical Inc that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

AEMD: Positive Takeaways from Plan to Expand Clinical Efforts

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Several medical centers actively screening patients for enrollment Aethlon Medical (NASDAQ:AEMD) hosted a call and provided a business update yesterday. The company’s lead product is the Hemopurifier®, an extracorporeal (i.e. outside of the body) blood filtration device that is designed to selectively remove harmful particles from the

Yahoo | February 15, 2022

Aethlon Medical''s (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 14, 2022

Aethlon Medical GAAP EPS of -$0.16 misses by $0.02, revenue of $0.02M misses by $0.19M

Aethlon Medical press release (NASDAQ:AEMD): FQ3 GAAP EPS of -$0.16 misses by $0.02.Revenue of $0.02M (-96.8% Y/Y) misses by $0.19M.

Seeking Alpha | February 14, 2022

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2021 and provided an update on recent developments.

Yahoo | February 14, 2022

Aethlon Medical Q3 2022 Earnings Preview (NASDAQ:AEMD)

Aethlon Medical (NASDAQ:AEMD) is scheduled to announce Q3 earnings results on Monday, February 14th, after market close.The consensus EPS Estimate is -$0.14 (+30.0% Y/Y) and the

Seeking Alpha | February 11, 2022

Outlook on the Blood Purification Equipment Global Market to 2031 - Aethlon Medical, Cerus and Infomed Among Others

DUBLIN , Feb. 7, 2022 /PRNewswire/ -- The "Global Blood Purification Equipment Market 2021-2031 by Product (Hemodialysis, Blood Filtration, CRRT, Hemoperfusion, Plasma Exchange Device), Portability (Portable, Stationary), Indication, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com''s offering. The global blood purification equipment market will reach $21.08 billion by 2031, growing by 5.5% annually over 2021-2031, driven by the increasing prevalence of blood-related diseases, rising geriatric population, technological innovations, growing healthcare expenditure, rising adoption of home based healthcare, and the rising health consciousness amid COVID-19 pandemic. This report is based on a comprehensive research of the entire gl...

Benzinga | February 7, 2022

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at 4:15 p.m. EST on Monday, February 14, 2022.

Yahoo | January 31, 2022

Longview Acquisition Corp. II (NYSE:LGV) & Aethlon Medical (NASDAQ:AEMD) Critical Survey

Longview Acquisition Corp. II (NYSE:LGV) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk. Analyst Ratings This is a breakdown of current recommendations and price targets for []

Transcript Daily | December 18, 2021

-$0.13 EPS Expected for Aethlon Medical, Inc. (NASDAQ:AEMD) This Quarter

Wall Street analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aethlon Medicals earnings. Aethlon Medical reported earnings of ($0.20) per share in the same quarter last year, which suggests a positive year-over-year growth []

Transcript Daily | December 16, 2021

Here's Why We're Not Too Worried About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | November 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7044 seconds.